POST-PANDEMIC BURDEN OF COVID-19 AMONG HIGH-RISK PATIENTS WITH ACUTE INFECTION: A CROSS-SECTIONAL SURVEY IN GERMANY
Author(s)
Mousumi Biswas, MPH, MSc1, james E. lucas, BSc2, Tendai Mugwagwa, PhD3, Eveline Otte im Kampe, MSc4, Mohammad A. Chaudhary, MSc, PhD5, Abid Kabir, MSc2, Emily Quinones, MSc2, James Piercy, Msc.2, Ruth Mokgokong, PhD3;
1Pfizer Inc., Director, HTA, Value & Evidence, New York City, NY, USA, 2Adelphi Real World, Bollington, United Kingdom, 3Pfizer Ltd., Tadworth, United Kingdom, 4Pfizer Pharma GmbH, Berlin, Germany, 5Pfizer Inc., Clarksburg, MD, USA
1Pfizer Inc., Director, HTA, Value & Evidence, New York City, NY, USA, 2Adelphi Real World, Bollington, United Kingdom, 3Pfizer Ltd., Tadworth, United Kingdom, 4Pfizer Pharma GmbH, Berlin, Germany, 5Pfizer Inc., Clarksburg, MD, USA
OBJECTIVES: We describe clinical characteristics, treatment, quality of life (QoL), and activities of daily living among high-risk patients with acute COVID-19 infection (<28 days).
METHODS: Data are from the Adelphi Real World COVID Disease Specific Programme™, a cross-sectional survey (with retrospective data capture) of healthcare professionals (HCPs) and patients at high-risk of developing severe COVID (aged ≥60 years) with acute COVID-19 infection in Germany from January to July 2024. HCPs reported patient demographics, clinical characteristics, treatment, and patients’ activities of daily living. Patients reported bothersome symptoms, QoL [using EQ-5D Visual Analogue Scale (EQ-VAS)] and impact of COVID-19 on QoL. Analyses were descriptive.
RESULTS: One hundred fifty-one HCPs recorded data for 200 high-risk acute COVID-19 patients, 98 of whom self-reported. Overall, 56.0% of patients were male, mean age was 68.1 years [SD:6.1]; 69.0% were retired or unemployed.
About 77.5% of patients had concomitant conditions, commonly hypertension (38.0%), chronic pulmonary disease (28.5%), and diabetes without chronic complications (27.0%). At survey date, 23.0% of patients were currently undergoing treatment for COVID-19, 8.0% had received treatment in the past, and 67.5% had not received treatment for the infection.
At survey date, most patients reported experiencing moderate (65.3%) or severe (14.3%) COVID-19 symptoms. Headaches (15.3%) were reported as the most bothersome symptom by patients, followed by shortness of breath or difficulty breathing (12.2%) and body aches (10.2%).
Patients reported a mean EQ-VAS score of 66.1 [SD:15.6]. 34.7% reported a moderate and 37.8% severe impact of COVID-19 on QoL.
HCPs reported 32.5% of patients required additional help for daily activities due to COVID-19 infection, most commonly shopping and meal preparation (60.0%), home maintenance (56.9%), and managing medications (41.5%).
CONCLUSIONS: High-risk patients with COVID-19 infection experienced notable symptom burden, impact on QoL and activities of daily living. Research is warranted to evaluate long-term impact in post-pandemic era.
METHODS: Data are from the Adelphi Real World COVID Disease Specific Programme™, a cross-sectional survey (with retrospective data capture) of healthcare professionals (HCPs) and patients at high-risk of developing severe COVID (aged ≥60 years) with acute COVID-19 infection in Germany from January to July 2024. HCPs reported patient demographics, clinical characteristics, treatment, and patients’ activities of daily living. Patients reported bothersome symptoms, QoL [using EQ-5D Visual Analogue Scale (EQ-VAS)] and impact of COVID-19 on QoL. Analyses were descriptive.
RESULTS: One hundred fifty-one HCPs recorded data for 200 high-risk acute COVID-19 patients, 98 of whom self-reported. Overall, 56.0% of patients were male, mean age was 68.1 years [SD:6.1]; 69.0% were retired or unemployed.
About 77.5% of patients had concomitant conditions, commonly hypertension (38.0%), chronic pulmonary disease (28.5%), and diabetes without chronic complications (27.0%). At survey date, 23.0% of patients were currently undergoing treatment for COVID-19, 8.0% had received treatment in the past, and 67.5% had not received treatment for the infection.
At survey date, most patients reported experiencing moderate (65.3%) or severe (14.3%) COVID-19 symptoms. Headaches (15.3%) were reported as the most bothersome symptom by patients, followed by shortness of breath or difficulty breathing (12.2%) and body aches (10.2%).
Patients reported a mean EQ-VAS score of 66.1 [SD:15.6]. 34.7% reported a moderate and 37.8% severe impact of COVID-19 on QoL.
HCPs reported 32.5% of patients required additional help for daily activities due to COVID-19 infection, most commonly shopping and meal preparation (60.0%), home maintenance (56.9%), and managing medications (41.5%).
CONCLUSIONS: High-risk patients with COVID-19 infection experienced notable symptom burden, impact on QoL and activities of daily living. Research is warranted to evaluate long-term impact in post-pandemic era.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
PCR172
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
SDC: Infectious Disease (non-vaccine)